170 related articles for article (PubMed ID: 23546688)
61. Interleukin-25 is upregulated in patients with systemic lupus erythematosus and ameliorates murine lupus by inhibiting inflammatory cytokine production.
Li Y; Wang R; Liu S; Liu J; Pan W; Li F; Li J; Meng D
Int Immunopharmacol; 2019 Sep; 74():105680. PubMed ID: 31200339
[TBL] [Abstract][Full Text] [Related]
62. Therapeutic potential of IL-27 in systemic lupus erythematosus.
Pan HF; Tao JH; Ye DQ
Expert Opin Ther Targets; 2010 May; 14(5):479-84. PubMed ID: 20350048
[TBL] [Abstract][Full Text] [Related]
63. Single immunoglobulin IL-1 receptor-related protein attenuates the lipopolysaccharide-induced inflammatory response in A549 cells.
Feng T; Yunfeng N; Jinbo Z; Zhipei Z; Huizhong Z; Li L; Tao J; Yunjie W
Chem Biol Interact; 2010 Feb; 183(3):442-9. PubMed ID: 19948160
[TBL] [Abstract][Full Text] [Related]
64. The inhibitory receptor toll interleukin-1R 8 (TIR8/IL-1R8/SIGIRR) is downregulated in chronic lymphocytic leukemia.
Vilia MG; Fonte E; Veliz Rodriguez T; Tocchetti M; Ranghetti P; Scarfò L; Papakonstantinou N; Ntoufa S; Stamatopoulos K; Ghia P; Muzio M
Leuk Lymphoma; 2017 Oct; 58(10):2419-2425. PubMed ID: 28278705
[TBL] [Abstract][Full Text] [Related]
65. Transcription factor specificity protein 1 modulates TGFβ1/Smad signaling to negatively regulate SIGIRR expression by human M1 macrophages stimulated with substance P.
Yamaguchi R; Sakamoto A; Yamaguchi R; Haraguchi M; Narahara S; Sugiuchi H; Yamaguchi Y
Cytokine; 2018 Aug; 108():24-36. PubMed ID: 29558695
[TBL] [Abstract][Full Text] [Related]
66. Increased ratio of Th17 cells to SIGIRR
Xiao JP; Wang DY; Wang XR; Yuan L; Hao L; Wang DG
Biomed Rep; 2018 Oct; 9(4):339-344. PubMed ID: 30233787
[TBL] [Abstract][Full Text] [Related]
67. MiR-340 suppresses CCl4-induced acute liver injury through exerting anti-inflammation targeting Sigirr.
Liu HH; Li AJ
Eur Rev Med Pharmacol Sci; 2020 Oct; 24(20):10687-10695. PubMed ID: 33155227
[TBL] [Abstract][Full Text] [Related]
68. IL-12 and IL-23/Th17 axis in systemic lupus erythematosus.
Larosa M; Zen M; Gatto M; Jesus D; Zanatta E; Iaccarino L; Inês L; Doria A
Exp Biol Med (Maywood); 2019 Jan; 244(1):42-51. PubMed ID: 30664357
[TBL] [Abstract][Full Text] [Related]
69. Negative Effects of SIGIRR on TRAF6 Ubiquitination in Acute Lung Injury In Vitro.
Tian F; Lu Q; Lei J; Ni Y; Xie N; Zhong D; Yang G; Si S; Jiang T
J Immunol Res; 2020; 2020():5097920. PubMed ID: 33123603
[TBL] [Abstract][Full Text] [Related]
70. In vivo study: Th1-Th17 reduction in pristane-induced systemic lupus erythematosus mice after treatment with tolerogenic Lactobacillus probiotics.
Mardani F; Mahmoudi M; Esmaeili SA; Khorasani S; Tabasi N; Rastin M
J Cell Physiol; 2018 Jan; 234(1):642-649. PubMed ID: 30078223
[TBL] [Abstract][Full Text] [Related]
71. SIGIRR modulates the inflammatory response in the brain.
Watson MB; Costello DA; Carney DG; McQuillan K; Lynch MA
Brain Behav Immun; 2010 Aug; 24(6):985-95. PubMed ID: 20394816
[TBL] [Abstract][Full Text] [Related]
72. IL-23/IL-17 axis in the pathogenesis and treatment of systemic lupus erythematosus and rheumatoid arthritis.
Farah Izati A; Wong KK; Che Maraina CH
Malays J Pathol; 2020 Dec; 42(3):333-347. PubMed ID: 33361714
[TBL] [Abstract][Full Text] [Related]
73. Immune complex-mediated cell activation from systemic lupus erythematosus and rheumatoid arthritis patients elaborate different requirements for IRAK1/4 kinase activity across human cell types.
Chiang EY; Yu X; Grogan JL
J Immunol; 2011 Jan; 186(2):1279-88. PubMed ID: 21160042
[TBL] [Abstract][Full Text] [Related]
74. Increased Expression of PPAR-γ Modulates Monocytes Into a M2-Like Phenotype in SLE Patients: An Implicative Protective Mechanism and Potential Therapeutic Strategy of Systemic Lupus Erythematosus.
Liu Y; Luo S; Zhan Y; Wang J; Zhao R; Li Y; Zeng J; Lu Q
Front Immunol; 2020; 11():579372. PubMed ID: 33584646
[TBL] [Abstract][Full Text] [Related]
75. Remission of systemic lupus erythematosus disease activity with regulatory cytokine interleukin (IL)-35 in Murphy Roths Large (MRL)/lpr mice.
Cai Z; Wong CK; Dong J; Chu M; Jiao D; Kam NW; Lam CW; Tam LS
Clin Exp Immunol; 2015 Aug; 181(2):253-66. PubMed ID: 25845911
[TBL] [Abstract][Full Text] [Related]
76. FcγRIIIa-Syk Co-signal Modulates CD4+ T-cell Response and Up-regulates Toll-like Receptor (TLR) Expression.
Chauhan AK; Moore TL; Bi Y; Chen C
J Biol Chem; 2016 Jan; 291(3):1368-86. PubMed ID: 26582197
[TBL] [Abstract][Full Text] [Related]
77. Up-regulation of MyD88s and SIGIRR, molecules inhibiting Toll-like receptor signaling, in monocytes from septic patients.
Adib-Conquy M; Adrie C; Fitting C; Gattolliat O; Beyaert R; Cavaillon JM
Crit Care Med; 2006 Sep; 34(9):2377-85. PubMed ID: 16850005
[TBL] [Abstract][Full Text] [Related]
78. Interleukin-6 receptor alpha blockade improves skin lesions in a murine model of systemic lupus erythematosus.
Birner P; Heider S; Petzelbauer P; Wolf P; Kornauth C; Kuroll M; Merkel O; Steiner G; Kishimoto T; Rose-John S; Soleiman A; Moriggl R; Kenner L
Exp Dermatol; 2016 Apr; 25(4):305-10. PubMed ID: 26739431
[TBL] [Abstract][Full Text] [Related]
79. IL-33: a potential therapeutic target in autoimmune diseases.
Wang S; Ding L; Liu SS; Wang C; Leng RX; Chen GM; Fan YG; Pan HF; Ye DQ
J Investig Med; 2012 Dec; 60(8):1151-6. PubMed ID: 23076162
[TBL] [Abstract][Full Text] [Related]
80. Role of interleukin-10 and interleukin-10 receptor in systemic lupus erythematosus.
Peng H; Wang W; Zhou M; Li R; Pan HF; Ye DQ
Clin Rheumatol; 2013 Sep; 32(9):1255-66. PubMed ID: 23708831
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
